News 2020 2020-12-29 Supplementary analyses to topline Phase II results reveal additional RP101 clinical strengths 2020-10-12 Redwood Pharma to present at Aktiespararnas Stora Aktiedagen Digitalt in Stockholm on November 30, 2020 2020-10-09 RP501: Redwood Pharma makes official name for mild dry eye therapeutic development program 2020-09-08 Redwood Pharma launches new development program for mild dry eye based on its proprietary IntelliGel platform 2020-08-28 Quarterly Report January–June 2020 2020-07-23 New patent for the use of estrogens in the treatment of DED to be issued in the US 2020-06-22 Video interview with CEO Martin Vidaeus – Positive Redwood Pharma status 2020-06-18 Redwood Pharma secures bridge financing and issues warrants 2020-05-18 Redwood Pharma will receive approximately SEK 2.1 million 2020-05-11 Quarterly report January – March 2020 2020-03-12 Live Webcast of the announcement of RP101 Phase II clinical results 2020-03-12 RP101 Phase II clinical results 2020-02-28 Redwood Pharma to present at BIO-Europe Spring 2020-02-14 Redwood Pharma AB (publ) Year-end report 2019 2020-02-10 Patent to be granted in China regarding IntelliGel 2019 2019-12-05 Video presentation (ENG) of clinical status of RP101 by CEO Martin Vidaeus 2019-11-27 Redwood Pharma arranging partnering meetings during JPMorgan Healthcare Conference 2020 in San Francisco 2019-11-19 Redwood Pharma AB Quarterly Report January – September 2019 2019-11-18 Redwood Pharma to present at BioStock Live in Stockholm on December 3, 2019 2019-11-12 Last patient completes treatment in RP101 Phase II clinical trial 2019-10-25 Redwood Pharma to attend BIO-Europe Nov. 10-12 in Hamburg 2019-08-13 Redwood Pharma to present at BioStock Live in Stockholm on August 27, 2019 2019-08-05 Last patient recruited in Redwood Pharma Phase II trial 2019-06-19 Update regarding financial situation 2019-06-18 Update regarding RP101 Phase II trial 2019-02-11 Redwood Pharma to Attend BIO-Europe 2019, Mar. 25 – 27 in Vienna for Partnering Discussions 2019-02-04 First patient treated in Redwood Pharma Phase II study 2019-01-07 Redwood Pharma receives its third and last national approval 2018 2018-12-14 Redwood Pharma receives approval from another drug authority – the Austrian 2018-11-12 Redwood Pharma initiates clinical trial 2018-10-02 New patent for IntelliGel on the way in the EU 2018-09-18 Redwood Pharma to Attend BIO-Europe 2018, Nov. 5 – 7 in Copenhagen for Partnering Discussions 2018-09-10 Redwood Pharma to present at Nordic Life Science Days in Stockholm on September 11, 2018 2018-08-29 Interim Report January – June 2018 2018-08-21 Come meet us when Redwood Pharma presents 2018-07-09 Redwood Pharma has submitted an application for the start of clinical trial 2018-06-13 Video Presentation (ENG) by Redwood Pharma June 11, 2018 2018-05-30 Redwood Pharma to present at NLSDays in Stockholm, Sep. 10-12, 2018 2018-04-26 Redwood Pharma’s new rights issue oversubscribed 2018-03-15 Redwood Pharma to execute New Rights Issue and takes important step in securing further financing 2018-03-08 Redwood Pharma acquires intellectual property rights 2018-02-26 Asian Pharmaceutical Firm to Evaluate IntelliGel® 2018-02-26 Positive meeting with Medical Products Agency prior to clinical Phase II trial 2018-02-23 Additional US patent to be granted regarding IntelliGel 2018-01-22 Redwood Pharma to Attend BIO-Europe 2018, Mar. 11 – 14 in Amsterdam for Partnering Discussions 2017 2017-12-04 Interview with CEO: Development throught toxicology and safety studies 2017-11-28 Redwood Pharma starts production of RP101 for clinical trials 2017-11-20 Toxicology and Safety Studies are Successfully Completed 2017-09-20 Redwood Pharma to Attend Bio-Europe 2017, Nov. 6 – 8 in Berlin for Partnering Discussions 2017-09-01 Redwood Pharma enters into agreement with CRO for clinical trial 2017-06-02 Redwood Pharma begins production of active ingredient in RP101 for Phase II studies 2017-03-15 Redwood Pharma initiates toxicological safety studies 2017-03-02 New US patent approved 2017-02-15 Redwood Pharma AB (publ) End of Year Report 2016 2017-02-13 Eye expert to support Redwood Pharma 2017-01-16 Redwood Pharma has developed a process for manufacture of the drug RP101 for coming safety studies 2016 2016-12-21 Development of Redwood Pharma’s RP101 ophthalmic therapy continues according to plan along with value-enhancing networking 2016-11-08 Redwood Pharma AB (publ) to present at Aktiespararna conference in Örebro on November 19, 2016 2016-10-07 Redwood Pharmas IntelliGel drug delivery platform demonstrates positive results in in vitro test 2016-09-20 Redwood Pharma AB appoints Ulf Björklund as Chief Medical Officer 2016-09-16 Market Trends Highlighted in Tear Film and Ocular Surface (TFOS) Conference in Montpellier Confirm Need for Redwood Pharmas Dry Eye Therapy 2016-08-30 Japanese patent granted for IntelliGel platform 2016-08-11 Redwood Pharma to present at French-Swedish Life Science Day 2016 2016-08-09 Redwood Pharma to attend leading conference on ocular tear film science 2016-07-11 Redwood Pharma attending OIS-ASRS Conference in San Francisco 2016-06-07 Redwood Pharma to Present at BIO 2016 in San Francisco 2016-02-23 Redwood Pharma raises SEK 6.6 million in private placement 2015 2015-06-24 Redwood Pharma licenses novel hydrogel drug delivery technology from Broda Technologies Latest presentation Stora Aktiedagen Göteborg Presentations Latest report Reports